Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation

Autor:	Weon Kim, J.M. Kim, Woo Shik Kim, Jong Shin Woo, Hyung Oh Kim, Young Shin Lee, Jung Myung Lee, Seung Woo Choi, Jin Bae Kim, Gyeong Won Jang, Hyemoon Chung
Rok vydání:	2021
Předmět:	medicine.medical_specialty anticoagulants Endothelium endothelium Article Dabigatran Internal medicine medicine Clinical endpoint atrial fibrillation cardiovascular diseases Endothelial dysfunction Reactive hyperemia Rivaroxaban business.industry Warfarin Atrial fibrillation General Medicine medicine.disease medicine.anatomical_structure Cardiology cardiovascular system Medicine atherosclerosis business medicine.drug
Zdroj:	Journal of Clinical Medicine Volume 10 Issue 19 Journal of Clinical Medicine, Vol 10, Iss 4332, p 4332 (2021)
ISSN:	2077-0383
Popis:	This study was designed to determine the efficacy of a new oral anticoagulant (NOAC) therapy for the prevention of endothelial dysfunction and atherosclerosis progression in patients with atrial fibrillation (AF). Sixty-five AF patients with a CHA2DS2-VASc score ≥2 without previous history of cardiovascular disease were registered and randomly assigned to either an NOAC group (dabigatran or rivaroxaban) or the warfarin group. Reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements reflecting endothelial function were taken using Endo-PAT2000. Carotid intima–media thickness (IMT) was measured at baseline, 12 months, and 24 months, and several biomarkers were also analyzed. For the primary end point, the reactive hyperemia index (RHI) for the NOAC group was 1.5 ± 0.4 and that for the warfarin group was 1.6 ± 0.5. The left and right carotid IMT was 0.7 mm in the NOAC groups and 0.8 mm in the warfarin group. At 12 months, RHI was 1.6 ± 0.3 for the dabigatran group, 1.6 ± 0.5 for the rivaroxaban group, and 1.6 ± 0.3 for the warfarin group. The three groups did not differ statistically with respect to change in left and right carotid IMT at 12 and 24 months, respectively. The biomarkers for endothelial function and atherosclerosis were not significantly different. There was a trend of reduced P-selectin levels in the NOAC group compared to the warfarin group. In patients with AF, there were no significant differences in the prevention of endothelial dysfunction and atherosclerosis progression between the NOAC and warfarin groups.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fbf1488aa6e4aa9921c0aa92614fc4f https://pubmed.ncbi.nlm.nih.gov/34640348 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.